Phase 1 trial of whole-parasite malaria vaccine to begin
According to this news bit:
"While most malaria vaccines in clinical development consist of recombinant or genetically engineered proteins that represent small portions of the parasite, Sanaria’s Plasmodium falciparum sporozoite vaccine candidate contains a weakened form of the entire malaria parasite. While unique to the malaria vaccine field, such live vaccines are used for other diseases including smallpox, polio, and measles. When the attenuated parasite is given to individuals, they are expected to become immune to malaria and not get sick."
You can read more about Clinical Trials at wikipedia.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment